Aldoxorubicin is for the patients. Endpoints met. Fda already contracted for sa path. http://markets.businessinsider.com/news/stocks/BRIEF-Cytrx-reports-statistically-significant-updated-results-from-pivotal-phase-3-trial-of-aldoxorubicin-in-patients-with-second-line-soft-tissue-sarcomas-CYTR-1001557562